AZNAstraZenecaRunning, no new patients
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Metastatic Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 895 (final count)
- Started
- Oct 24, 2023
- Main results expected
- Aug 17, 2026
- Fully finished
- Nov 12, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)
Measured over: Up to approximately 6 years
Overall Survival (OS), in PD-L1-negative participants.
Measured over: Up to approximately 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05984277 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC